During the past decade, Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz conducted 51 clinical trials. In the 10-year time frame, 51 clinical trials started and 37 clinical trials were completed, i.e. on average, 72.5% percent of trials that started reached the finish line to date. In the past 5 years, 21 clinical trials started and 23 clinical trials were completed. i.e. 109.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz" #1 sponsor was "Hoffmann-La Roche" with 10 trials, followed by "Amgen" with 7 trials sponsored, "Janssen Research & Development, LLC" with 7 trials sponsored, "Pfizer" with 6 trials sponsored and "Takeda" with 6 trials sponsored. Other sponsors include 34 different institutions and companies that sponsored additional 34 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz" #1 collaborator was "Merck Sharp & Dohme LLC" with 3 trials as a collaborator, "Breast International Group" with 2 trials as a collaborator, "Novartis" with 2 trials as a collaborator, "Takeda Development Center Americas, Inc." with 2 trials as a collaborator and "Alliance Foundation Trials (AFT)" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz" are "Ulcerative Colitis" (9 trials), "Prostate Cancer" (5 trials), "Colitis, Ulcerative" (4 trials), "Crohn's Disease" (4 trials) and "Breast Cancer" (3 trials). Many other conditions were trialed in "Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz" in a lesser frequency.

Most popular intervention types in "Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz" are "Drug" (70 trials), "Other" (9 trials) and "Biological" (5 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (29 trials), "Carboplatin" (6 trials), "Cisplatin" (5 trials), "Gemcitabine" (4 trials) and "Paclitaxel" (4 trials). Other intervention names were less common.

The vast majority of trials in "Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz" are 63 trials for "All" genders, 7 trials for "Male" genders and 5 trials for "Female" genders.

Currently, there are NaN active trials in "Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz". undefined are not yet recruiting, 16 are recruiting, 12 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 36 completed trials in Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz, undefined suspended trials, and 10 terminated clinical trials to date.

Out of the total trials that were conducted in Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz, 0 "Phase 1" clinical trials were conducted, 12 "Phase 2" clinical trials and 58 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 1 trials that are defined as “Not Applicable".

Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz has several departments that took part in Clinical trials: "Borsod-Abauj-Zemplen Megyei Korhaz Es Egyetemi Oktato Korhaz; Onkologiai Osztaly" - 12 trials, "B-A-Z Megyei Korhaz es Egyetemi Oktato Korhaz Stroke, Er- es Neurologiai, Toxikologiai Osztaly" - 2 trials